Tara Barto, MD
Pulmonary Disease · Houston, TXNPI 1073729455
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.2% of the total across 57 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Philips North America LLC at 35.6% of the total. Reporting peaked in 2019 at $1,347 and has fallen 79.1% since, to $281 in 2025.
Across 57 payments — averaging $45.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$930
- Vertex$334
- Gilead$248
- Advanced Respiratory, Inc$203
- Electromed, Inc.$191
- AbbVie$170
- plus $535 from 7 others
Across 14 payments — averaging $37,642 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$527K
What the payments were for
- Food & beverage$2,51196%
- Education$241%
- Gifts$763%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 23 | $930 |
| Vertex | 7 | $334 |
| Gilead | 4 | $248 |
| Advanced Respiratory, Inc | 2 | $203 |
| Electromed, Inc. | 3 | $191 |
| AbbVie | 5 | $170 |
| Mylan Specialty L.p. | 2 | $161 |
| Baxter Healthcare | 3 | $156 |
| Chiesi USA, Inc. | 2 | $98 |
| Monaghan Medical Corporation | 1 | $61 |
| Insmed, Inc. | 3 | $51 |
| Intra-sana Laboratories | 1 | $6 |
| United Therapeutics Corporation | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- inCourage$341
- The Vest System Model 105 Home Care$161
- Creon$125
- ALYFTREK$115
How this compares
$2,611 in reported general payments places this provider in the 55th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 122 | $3,158,096 |
| KalydecoIvacaftor | 15 | $463,493 |
| CaystonAztreonam Lysine | 30 | $359,870 |
| CreonLipase/Protease/Amylase | 29 | $175,118 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $139,414 |
| ZenpepLipase/Protease/Amylase | 13 | $97,789 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $45,129 |
| Breo ElliptaFluticasone/Vilanterol | 50 | $23,186 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $8,538 |
| Spiriva HandihalerTiotropium Bromide | 15 | $7,852 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $6,107 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $5,626 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 123 | $2,958 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $2,612 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $2,592 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| VertexTrikafta, Kalydeco | $334 | $3,621,589137 claims |
| GileadCayston | $248 | $359,87030 claims |
| AbbVieCreon | $170 | $175,11829 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Houston
- Nicola HananiaHouston$1.3M
- Sandeep SahayHouston$378K
- Zeenat SafdarHouston$291K
- Howard HuangHouston$194K
- Brandy McKelvyHouston$168K
- Alexander StadnykHouston$158K
- Lisa KopasHouston$120K
- Sandeep GuptaHouston$118K
- Roberto CasalHouston$113K
- Dileep PuppalaHouston$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.